Platinum-perovskite nanocomposite-based Exosensor for specific detection of prostate cancer in clinical settings
Microchimica Acta, cilt.191, sa.10, 2024 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 191 Sayı: 10
- Basım Tarihi: 2024
- Doi Numarası: 10.1007/s00604-024-06655-z
- Dergi Adı: Microchimica Acta
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aerospace Database, Analytical Abstracts, Aqualine, Aquatic Science & Fisheries Abstracts (ASFA), Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, Chimica, Communication Abstracts, Food Science & Technology Abstracts, Metadex, Pollution Abstracts, Civil Engineering Abstracts
- Anahtar Kelimeler: Differential pulse voltammetry, Electrochemical Exosensor, Exosomes, Extracellular vesicles, Modified glassy carbon electrode, Perovskite, Prostate-specific antigen
- Yıldız Teknik Üniversitesi Adresli: Evet
Özet
Exosomes, extracellular vesicles (EVs) with an average size of 50–150 nm, transfer various biomolecules and exchange signaling molecules between cells in a paracrine manner. Molecular investigations have revealed that EVs can reflect real-time metabolic changes in normal- and cancer-origin cells and thus harbor valid diagnostic biomarkers. Despite these advantages, the detection of low concentrations of cancer cell EVs in biological fluids is still a great challenge. Here, a new electrochemical Exosensor based on platinum-perovskite is developed for the direct detection of EVs using a biotinylated monoclonal CD63 antibody as a capture element. The label-free method exhibited higher sensitivity with a lower limit of quantification of 2000 EVs/µL with a dynamic linear range (LDR) of 2000 to 14,000 EVs/μL compared with other available methods. To enhance the selectivity of detection, EVs were simultaneously sandwiched between secondary antibodies of PSA (prostate-specific antigen), as an FDA-approved prostate cancer biomarker. Data indicated that this Exosensor can distinguish normal and cancer EVs in samples from healthy individuals and prostate cancer patients. Taken together, this technology offers a unique approach to label-free quantification of EVs and cancer detection in the early stages. Graphical abstract: (Figure presented.).